Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Extracorporeal or ex vivo removal of antibodies or immune...
Patent
1996-10-22
1999-02-09
Budens, Robert D.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Extracorporeal or ex vivo removal of antibodies or immune...
530413, A61K 3909
Patent
active
058690476
ABSTRACT:
The subject invention pertains to methods of treating immunocompromised patients, such as individuals infected with HIV, that exhibit elevated levels of IgA relative to IgG. The use of IgA-binding compositions immobilized onto a support matrix to extracorporeally remove IgA molecules from a sample or biological fluid for therapeutic purposes is provided by the present invention. The subject invention further pertains to novel polypeptides which bind in a specific manner to human IgA. The polypeptides of the present invention comprise an IgA-binding region from an IgA-binding protein of Group B streptococcal bacteria.
REFERENCES:
patent: 4223672 (1980-09-01), Terman et al.
patent: 4757134 (1988-07-01), Blake et al.
patent: 4801449 (1989-01-01), Balint, Jr. et al.
patent: 5122112 (1992-06-01), Jones
patent: 5210183 (1993-05-01), Lindahl et al.
patent: 5413918 (1995-05-01), Faulmann
Apicella, M.A. et al. (1986) "Bactericidal Antibody Response of Normal Human Serum to the Lipooligosaccharide of Neisseria gonorrhoeae," The Journal of Infectious Diseases, Vol. 153, No. 3, Mar. pp. 520-526.
Birx, D.L. et al. (1991) "Immunologic Parameters in Early-Stage HIV-Seropositive Subjects Associated with Vaccine Responsiveness," Journal of Acquired Immune Deficiency Syndromes, 4:188-196.
Conlon, C.P. (1993) "The immunocompromised traveller," British Medical Bulletin, Vol. 49, No. 2, pp. 412-422.
Eckrich, R.J. et al. (1993) "Laboratory tests to exclude IgA deficiency in the investigation of suspected anti-IgA transfusion reactions," Transfusion, Vol. 33,No. 6, pp. 488-492.
Filipovich, A..H., et al. "Lymphoproliferative Disorders and Other Tumors Complicating Immunodeficiencies," Immunodeficiency, Vol. 5, pp. 91-112.
Griffis, J.M. (1975) "Bactericidal Activity of Meningococcal Antisera," The Journal of Immunology, Vol. 114, No. 6, Jun., pp. 1779-1784.
Griffis, J.M. and M.A. Bertram (1977) "Immunoepidemiology of Meningococcal Disease in Military Recruits. II. Blocking of Serum Bactericidal Activity by Circulating IgA Early in the Course of Invasive Disease," The Journal of Infectious Diseases, Vol. 136, No. 6, Dec., pp. 733-739.
Griffis, J.M. (1982) "Serum IgA: Modulation of Complement Activation and Induction of Susceptibilty to Bacterial Dissemination," Infection 10, Nr. 4, pp. 246-251.
Griffis, J.M. (1983) "Biologic Function of the Serum IgA System: Modulation of Complement-Mediated Effector Mechanisms and Conservation of Antigenic Mass, " Annals New York Academy of Sciences, pp. 697-707.
Griffis, J.M. (1983) "IgA Blocks IgM and IgG-Initiated Immune Lysis by Separate Molecular Mechanisms," The Journal of Immunology, Vol. 130, No. 6, Jun., pp. 2882-2885.
Jerlstrom, P.G. et al. (1991) "The IgA-binding .beta. antigen of the c protein complex of Group B streptococci: sequence determination of its gene and detection of two binding regions," Molecular Microbiology, 5(4), 843-849.
Lim, E.C. et al. (1993) "In Vitro Studies to Explain High Renal Allograft Survival in IgA Nephropathy Patients," Transplantation, Vol. 55, No. 5, May, 996-999.
Misbah, S.A. and H.M. Chapel (1993) "Adverse Effects of Intravenous Immunoglobulin," Drug Safety 9 (4): 254-262.
Musher, D.M. et al. (1984) "Immunoglobulin A from Bronchopulmonary Secretions Blocks Bactericidal and Opsonizing Effects of Antibody to Nontypable Haemophilus influenzae, "Infection and Immunity, Vol. 45, No. 1, Jul., pp. 36-40.
Quesnal, A. et al. (1994) "Is there IgA of gut mucosal origin in the serum of HIV1 infected patients?" Gut, 35: 803-808.
Quesnal, A. et al. (1994) "Early impairment of gut mucosal immunity in HIV-1 infected children,"Clin Exp Immunol, 97:380-385.
Rhoads, J.L. et al. (1991) "Safety and Immunogenicity of Multiple Conventional Immunizations Administered During Early HIV Infection," Journal of Acquired Immune Deficiency Syndromes, 4:724-731.
Russell-Jones, G.J. et al. (1980) "The Ability to IgA to Inhibit the Complement-Mediated Lysis of Target Red Blood Cells Sensitized With IgG Antibody, "Molecular Immunology, Vol. 17 pp. 1173-1180.
Russell-Jones, G.J. et al. (1981) "Inhibition of Cutaneous Anaphylaxis and Arthus Reactions in the Mouse by Antigen Specific IgA,"Int. Archs Alergy appl. Immun. 66:316-325.
Sandler, S.G. et al. (1995) "IgA Anaphylactic Transfusion Reactions," Transfusion Medicine Reviews, Vol IX, No 1, Jan. pp. 1-8.
Taylor, P.W. (1972) "An Antibacteriocidal Factor in the Serum of Two Patients with Infections of the Upper Urinary Tract,"Clinical Science 43, 23-30.
Blake Laboratories, Inc.
Budens Robert D.
LandOfFree
Methods for therapeutically treating immunocomprised persons does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for therapeutically treating immunocomprised persons, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for therapeutically treating immunocomprised persons will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1946654